Former director general: Health Canada needs broader drug safety powers

Silversides, Ann
May 2006
CMAJ: Canadian Medical Association Journal;5/9/2006, Vol. 174 Issue 10, p1395
Academic Journal
Focuses on the views of Dr. Robert Peterson, a pediatrician who left Health Canada and became the director of the British Columbia Child and Youth Health Research Network, regarding the need of Health Canada for broader powers to assess the safety of new prescription drugs. Response of Health Canada to some of the issues raised by Peterson; Suggestion of Peterson for insurance companies and employers; Involvement of Peterson with regulatory matters.


Related Articles

  • Health Canada drug approval process slower than in Europe and US.  // British Columbia Medical Journal;Jun2013, Vol. 55 Issue 5, p234 

    The article deals with a report the Fraser Institute which revealed that the drug approval process by Health Canada takes nearly a year which is slower than in Europe and the U.S.

  • Unauthorised products warning in Canada.  // Reactions Weekly;2/27/2010, Issue 1290, p4 

    The article reports on a warning issued by Health Canada to customers about unauthorised products sold under the "OM Fusion Distributors LLC" label stating that the products may cause life threatening reactions.

  • New table helps generic co.'s keep safety labelling up to date.  // Reactions Weekly;3/16/2013, Issue 1444, p5 

    The article reports that the Health Canada launched a table on its website focused on informing generic drug manufacturers about the safety labelling changes to the Product Monographs, pharmaceutical brand.

  • Pricing Under Microscope.  // Chain Drug Review;7/19/2010, Vol. 32 Issue 12, p64 

    The article reports on the release of the discussion paper "Generic Drug Pricing and Access in Canada: What are the Implications?" by the Health Council of Canada.

  • Antipsychotics and newborns. Kondro, Wayne // CMAJ: Canadian Medical Association Journal;8/9/2011, Vol. 183 Issue 11, pE721 

    The article reports that Canada's Health Canada is following the U.S. lead and revised labelling requirements for a class of antipsychotic drugs being used during pregnancies.

  • Health Canada Releases Resource Kit To Assist Health Professionals. .  // Journal of the Canadian Dental Association;Sep1998, Vol. 64 Issue 8, p548 

    The article focuses on the resource kit entitled "Medication Matters: How You Can Help Seniors Use Medication Safely" published by the agency Health Canada.

  • Health Canada issues reminder of benzocaine risks.  // Reactions Weekly;5/7/2011, Issue 1350, p3 

    This article reports on the move of Health Canada to remind the people of the risks associated with the use of topical benzocaine.

  • Health Canada seeks policy on DEHP.  // Plastics News;2/18/2002, Vol. 13 Issue 50, p3 

    Reports Health Canada recommendation on the usage and exposure of di(2-ethylhexyl)phthalate (DEHP) in Toronto, Ontario. Advisory panel of medical professionals on DEHP regulation; Use of DEHP; Concerns on the health of patients.

  • Health Canada cracks down on poppers. SALERNO, ROB // Xtra West (Vancouver);7/18/2013, Issue 519, p12 

    The article reports on the warning of Health Canada regarding the sale of alkyl nitrate products, known as poppers, which classified as a drug under the Food and Drug Act, in Canada in 2013.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics